All News

CAR T-cell therapies such as liso-cel and axi-cel in DLBCL were the focal points during an Around the Practice program at the 2025 Tandem Meeting.

Kit Yu Lu, MD, discusses the applications of T-DXd and sacituzumab govitecan for patients with breast cancer.

Approximately 10% of patients discontinued treatment with avutometinib/defactinib due to toxicity in the phase 2 RAMP 201 trial.

CRS and ICANS occurrence were comparable for patients with relapsed/refractory multiple myeloma 75 years and older vs those younger than 75.

The B7-H3 CAR T-cell therapy showed positive survival results for younger patients with diffuse intrinsic pontine glioma in a phase 1 trial.

This case report and literature review emphasize that ICI-IA should not be ruled out based on the presence of synovial fluid with elevated WBC with a neutrophil predominance. Early steroid use should be considered.

Shannon L. Puhalla, MD, delves into the clinical application, efficacy, and safety profiles of T-DXd and sacituzumab govitecan for patients with breast cancer.

Teal Wand showed a 95% positive percent agreement when screening for cervical cancer.

Response rates appeared to be higher with avutometinib plus defactinib vs avutometinib alone in the phase 2 RAMP 201 study.

Data from the POD1UM-303/InterAACT2 trial support the approval of retifanlimab/chemotherapy for patients with squamous cell carcinoma of the anal canal.

Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, highlight exciting trials in the genitourinary cancer space expected to be presented at 2025 ASCO.

Data from the KEYNOTE-B96 trial also show a significant overall survival improvement with pembrolizumab-based treatment in PD-L1–positive disease.

This retrospective study included 64 patients with LMD, with primary cancers represented in the diagnosis-specific Graded Prognostic Assessment (DS-GPA) at a single institution over 5 years.

Jennifer Moliterno, MD, FAANS, highlights post-operative complications that may arise after neurosurgery.

Patients who respond to avutometinib/defactinib may be maintained on treatment for long periods of time, says Rachel N. Grisham, MD.

Data from the phase 2 LUMINOSITY study support the FDA approval of telisotuzumab vedotin in this non–small cell lung cancer population.

Among 18 patients with central nervous system lymphoma treated with the ibrutinib/nivolumab combination regimen, 3 had remission beyond 2 years.

Data from the LITESPARK-015 trial supported the FDA’s decision to approve belzutifan monotherapy in patients with advanced, unresectable, or metastatic PPGL.

The safety profile of loncastuximab tesirine plus glofitamab was consistent with the known profiles of the individual agents.

AI has the potential to change practice patterns, improve imaging, and inform treatment planning for patients with brain tumors.

Anaplastic large cell lymphoma is a rapidly growing and aggressive hematological malignancy. This case highlights the rarity of isolated intradural extramedullary manifestations in the pediatric population.

Jennifer Moliterno, MD, FAANS, discusses current neurosurgical strategies for maximizing safe resection in newly diagnosed high-grade gliomas.

Oncology clinicians can effectively collaborate with neuroradiologists using advanced techniques to improve brain tumor characterization.

Neil M. Iyengar, MD, highlighted the recent T-DXd and Dato-DXd approvals in breast cancer.

Ten-year data from the phase 3 APHINITY trial will be presented at the 2025 European Society for Medical Oncology Breast Cancer Congress.

Jennifer Moliterno, MD, FAANS, discusses current neurosurgical strategies for newly diagnosed high-grade gliomas.